ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1403

Development, Validation and Clinical Use of Health-Related Behaviour Health Fitness Questionnaire (HR-BHF) in Indian (Asian) Subjects Attending a Community Rheumatology Center

MANJIT SALUJA1 and ARVIND CHOPRA2, 1CENTER FOR RHEUMATIC DISESAES, Pune, Maharashtra, India, 2CENTER FOR RHEUMATIC DISEASES, Pune, Maharashtra, India

Meeting: ACR Convergence 2024

Keywords: health status, Outcome measures, quality of life, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 17, 2024

Title: Research Methodology Poster – ARP

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Our patients often express concerns related to ‘wellbeing’ that are not routinely attended during  standard care (including QOL). Alternatively, these concerns are important components of holistic care systems. Wellbeing is a multidimensional complex construct. We present some important aspects of a novel indigenous clinically oriented questionnaire (HR-BHF) developed by us to assess wellbeing and enrich patient assessment and satisfaction in our practice.

Methods: Trained paramedics recorded concerns (ad verbatim) of wellbeing (construct of interest) volunteered by patients (chronic RA); 20 most frequent individual items shortlisted  (Oct-Dec 2019). A suitable expert committee finalized 9 items (see below) by a standard consensus approach for inclusion in the self-reported HR-BHF. They approved introductory explanatory note and standard translations. They reviewed pilot testing (Feb-April 2020) in 103 RA patients and 300 healthy unrelated subjects (HC) and few corrections were made to improve comprehension and administration (HR-BHF, CRD, Pune 2020 version). The face and  content validity of HR-BHF was also endorsed. Each item response was marked (│) on a standard 0-100 mm VAS (horizontal, no interval mark); 100 being the best outcome for general health, energy, bowel, happiness and appetite and  0 (reverse scoring ) indicate the best outcome for anxiety, fatigue, stress and sleep. In the final score (optimum 900), reverse score was adjusted (ascendency towards 100). Further validation (Jan 2023-May 2024) was carried out in 2  clinic based prospective cohorts (C) of RA patients- RAC1[ 68 subjects, mean age 53 years ( ± 10.4 SD] and RAC 2 [ 209 subjects, mean age 53.6 years (±10.6 SD), 185 women; mean DAS 28 ESR 3.79 (± 1.29 SD), mean total HAQ score 4.12 (± 3.12 SD]. All study subjects were volunteers (oral consent) and selected in no particular order; RA was on regular standard treatment. Standard statistics (including reliability and validity) carried out on MS Excel data sheets (significant P< 0.05).

Results: (1) Pilot testing: 82% subjects and 92% respectively reported ‘no difficulty’ (understanding) and ‘useful/very useful’ (medical care). Mean item scores (mm) were higher in HC (p< 0.05); see Figure below (HC and RA groups, reverse score not adjusted). (2) RAC 1: HR-BHF score -Cronbach’ s Alfa- 0.65(test), 0.80 (retest 36-48 hours later);Intraclass Coeficient-0.81(generalizability limited to  trained personnel) (3)  RAC 2: Cronbach’ s Alfa- 0.69; Correlation (r):Correlation matrix/item score shown below. Several ‘r’ was moderate and significant including HR-BHF total & DAS 28 ESR/HAQ; Multivariable linear regression: 48% variation in GH explained by other HR-BHF items, Age, DAS and HAQ,  Significant predictors-fatigue, energy, sleep, DAS, HAQ (4) Change/effect size (HR-BHF) over time will be presented (5) Limitations-single centre, floor/ceiling effect, multidimensional (overlap) and limited items (wellbeing), COVID pandemic influence (pilot testing).

Conclusion: HR-BHF was a reliable and valid measure of general wellbeing in RA in our setting. It may augment value-based patient care. Further research is required to show its potential universal generic use in health and disease.  

Supporting image 1

HR BHF CORRELATION MATRIX I

Supporting image 2

HR BHF PILOT TESTING-MEAN ITEM SCORES


Disclosures: M. SALUJA: None; A. CHOPRA: None.

To cite this abstract in AMA style:

SALUJA M, CHOPRA A. Development, Validation and Clinical Use of Health-Related Behaviour Health Fitness Questionnaire (HR-BHF) in Indian (Asian) Subjects Attending a Community Rheumatology Center [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/development-validation-and-clinical-use-of-health-related-behaviour-health-fitness-questionnaire-hr-bhf-in-indian-asian-subjects-attending-a-community-rheumatology-center/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/development-validation-and-clinical-use-of-health-related-behaviour-health-fitness-questionnaire-hr-bhf-in-indian-asian-subjects-attending-a-community-rheumatology-center/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology